Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) – Equities researchers at HC Wainwright lifted their Q2 2024 earnings per share estimates for shares of Cytokinetics in a research report issued on Thursday, May 23rd. HC Wainwright analyst J. Pantginis now expects that the biopharmaceutical company will post earnings per share of ($1.16) for the quarter, up […]
Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) has received a consensus rating of “Moderate Buy” from the seventeen brokerages that are currently covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating on the company. The average 12 month price objective among […]
Cytokinetics (NASDAQ:CYTK – Free Report) had its price target reduced by Needham & Company LLC from $108.00 to $72.00 in a research report report published on Thursday, Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. CYTK has been the subject of several other research reports. JMP Securities lowered their price […]
Cytokinetics (NASDAQ:CYTK – Free Report) had its price objective cut by Raymond James from $92.00 to $70.00 in a report published on Thursday morning, Benzinga reports. They currently have an outperform rating on the biopharmaceutical company’s stock. A number of other brokerages have also recently commented on CYTK. Mizuho reduced their price target on shares […]
Cytokinetics (NASDAQ:CYTK – Free Report) had its price target reduced by Barclays from $100.00 to $95.00 in a report issued on Thursday, Benzinga reports. They currently have an overweight rating on the biopharmaceutical company’s stock. Other equities analysts also recently issued reports about the company. HC Wainwright restated a buy rating and issued a $94.00 […]